Antisense Oligonucleotide Treatment of Inflammatory Bowel Diseases

Our expanding knowledge of inflammatory mediator pathways has created new options for the management of Crohn’s disease and ulcerative colitis (1 ). In the past decade, the differential immune activation of intestinal and peripheral immune systems has been identified, and these observations have rapidly moved basic science observations to the bedside, as biological therapies continue to increase.